Wordt geladen...
A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies
BACKGROUND: Sunitinib treatment results in a compensatory increase in plasma VEGF levels. Acute withdrawal of sunitinib results in a proliferative withdrawal flare, primarily due to elevated VEGF levels. Concurrent sunitinib plus bevacizumab is poorly tolerated with high (37 %) incidence of microang...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4200479/ https://ncbi.nlm.nih.gov/pubmed/24414551 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2373-9 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|